Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration